

## (2*R*,6*S*)-6-Amino-2-(2-thienyl)-1,4-thiazepan-5-one

Dan-Hua Wang,<sup>a,b</sup> Yuan-Jiang Pan<sup>a</sup> and Xiu-Rong Hu<sup>c\*</sup>

<sup>a</sup>Chemistry Department, Zhejiang University, Hangzhou, Zhejiang 310027, People's Republic of China, <sup>b</sup>Zhejiang Huahai Pharmaceutical Co. Ltd, Linhai, Zhejiang 317024, People's Republic of China, and <sup>c</sup>Center of Analysis and Measurement, Zhejiang University, Hangzhou, Zhejiang 310028, People's Republic of China

Correspondence e-mail:  
 huxiurong@yahoo.com.cn

### Key indicators

Single-crystal X-ray study  
 $T = 298\text{ K}$   
 $\text{Mean } \sigma(\text{C-C}) = 0.002\text{ \AA}$   
 $R\text{ factor} = 0.025$   
 $wR\text{ factor} = 0.069$   
 Data-to-parameter ratio = 18.9


For details of how these key indicators were automatically derived from the article, see  
<http://journals.iucr.org/e>.

In the title compound,  $C_9H_{12}N_2OS_2$ , the thiazepane ring adopts a chair conformation. The molecules are linked into chains via  $N-\text{H}\cdots\text{O}$  hydrogen bonds.

Received 28 April 2006  
 Accepted 10 May 2006

### Comment

The title compound, (I), is a key intermediate used in the preparation of temocapril, one kind of angiotensin-converting enzyme inhibitor against glutamate-induced neurotoxicity (Ishizuka *et al.*, 1997; Yanagisawa *et al.*, 1987). All the geometrical parameters for (I) lie within their expected ranges (Allen *et al.*, 1987). The thiazepane ring adopts a chair conformation, with atoms S1, C3 and N1 having deviations of 0.823 (2), -1.118 (2) and -1.120 (2)  $\text{\AA}$ , respectively, from the least-squares plane through the other four atoms (Fig. 1). The amino and carbonyl groups are involved in intramolecular and intermolecular  $N-\text{H}\cdots\text{O}$  hydrogen bonds (Table 2). An intermolecular hydrogen bond links molecules into a ribbon motif extending along the  $a$  axis (Fig. 2).




### Experimental


The material supplied by Zhejiang Huahai Pharmaceutical Co. Ltd was an enantiomer, the specific rotation at 293 K being +49.5° ( $c = 1.0$ , DMF). It was recrystallized from ethanol–ethyl acetate (4:1 *v/v*) by slow evaporation, giving colorless crystals of (I) suitable for X-ray diffraction.

### Crystal data

$C_9H_{12}N_2OS_2$	$Z = 4$
$M_r = 228.33$	$D_x = 1.420\text{ Mg m}^{-3}$
Orthorhombic, $P2_12_12_1$	Mo $K\alpha$ radiation
$a = 6.314 (3)\text{ \AA}$	$\mu = 0.47\text{ mm}^{-1}$
$b = 9.785 (3)\text{ \AA}$	$T = 298 (1)\text{ K}$
$c = 17.289 (6)\text{ \AA}$	Chunk, colorless
$V = 1068.2 (7)\text{ \AA}^3$	$0.34 \times 0.32 \times 0.26\text{ mm}$

**Figure 1**

The molecular structure and atom-numbering scheme for (I). Displacement ellipsoids are drawn at the 50% probability level.

**Figure 2**

Molecular chain in (I). Displacement ellipsoids are drawn at the 30% probability level and dashed lines indicate hydrogen bonds.

#### Data collection

Rigaku R-AXIS RAPID diffractometer

$\omega$  scans

Absorption correction: multi-scan (ABSCOR; Higashi, 1995)

$T_{\min} = 0.859$ ,  $T_{\max} = 0.886$

#### Refinement

Refinement on  $F^2$

$R[F^2 > 2\sigma(F^2)] = 0.025$

$wR(F^2) = 0.069$

$S = 1.04$

2442 reflections

129 parameters

H-atom parameters constrained

$w = 1/[0.0004F_o^2 + \sigma(F_o^2)]/(4F_o^2)$   
 $(\Delta/\sigma)_{\max} < 0.001$

10534 measured reflections  
2442 independent reflections  
2239 reflections with  $F^2 > 2\sigma(F^2)$   
 $R_{\text{int}} = 0.022$   
 $\theta_{\max} = 27.5^\circ$

$\Delta\rho_{\max} = 0.31 \text{ e } \text{\AA}^{-3}$   
 $\Delta\rho_{\min} = -0.26 \text{ e } \text{\AA}^{-3}$   
Extinction correction: Larson (1970)  
Extinction coefficient: 45 (5)  
Absolute structure: Flack (1983),  
1008 Friedel pairs  
Flack parameter: 0.006 (7)

**Table 1**  
Selected bond lengths (Å).

S1—C1	1.8254 (15)	O1—C3	1.2408 (18)
S1—C5	1.7938 (17)	N1—C2	1.459 (2)
S2—C6	1.7291 (16)	N1—C3	1.336 (2)
S2—C9	1.705 (2)	N2—C4	1.458 (2)

**Table 2**  
Hydrogen-bond geometry (Å, °).

$D—H \cdots A$	$D—H$	$H \cdots A$	$D \cdots A$	$D—H \cdots A$
N1—H1O1 <sup>i</sup> $\cdots$ O1 <sup>i</sup>	0.86	2.09	2.945 (2)	177
N2—H2O1 <sup>ii</sup> $\cdots$ O1 <sup>ii</sup>	0.86	2.32	3.161 (2)	165
N2—H2O2 <sup>ii</sup> $\cdots$ O1	0.87	2.48	2.784 (2)	101

Symmetry codes: (i)  $x + \frac{1}{2}, -y + \frac{1}{2}, -z$ ; (ii)  $x - \frac{1}{2}, -y + \frac{1}{2}, -z$ .

The two H atoms of the  $\text{NH}_2$  group were located in difference Fourier maps and refined as riding on the N atom with the as-found N—H distances and with  $U_{\text{iso}}(\text{H}) = 1.2U_{\text{eq}}(\text{N})$ . All other H atoms were placed in calculated positions with N—H = 0.86 Å and C—H = 0.93–0.98 Å, and constrained to ride on their parent atoms, with  $U_{\text{iso}}(\text{H}) = 1.2U_{\text{eq}}(\text{carrier atom})$ .

Data collection: *PROCESS-AUTO* (Rigaku, 1998); cell refinement: *PROCESS-AUTO*; data reduction: *CrystalStructure* (Rigaku/MSC, 2004); program(s) used to solve structure: *SHELXS97* (Sheldrick, 1997); program(s) used to refine structure: *CRYSTALS* (Betteridge *et al.*, 2003); molecular graphics: *ORTEP-3 for Windows* (Farrugia, 1997); software used to prepare material for publication: *CrystalStructure*.

#### References

- Allen, F. H., Kennard, O., Watson, D. G., Brammer, L., Orpen, A. G. & Taylor, R. (1987). *J. Chem. Soc. Perkin Trans. 2*, pp. S1–19.
- Betteridge, P. W., Carruthers, J. R., Cooper, R. I., Prout, K. & Watkin, D. J. (2003). *J. Appl. Cryst.* **36**, 1487.
- Farrugia, L. J. (1997). *J. Appl. Cryst.* **30**, 565.
- Flack, H. D. (1983). *Acta Cryst. A* **39**, 876–881.
- Higashi, T. (1995). *ABSCOR*. Rigaku Corporation, Tokyo, Japan.
- Ishizuka, H., Konno, K. & Naganuma, H. (1997). *J. Pharmacol. Exp. Ther.* **280**, 1304–1311.
- Larson, A. C. (1970). *Crystallographic Computing*, edited by F. R. Ahmed, pp. 291–294. Copenhagen: Munksgaard.
- Rigaku (1998). *PROCESS-AUTO*. Rigaku Corporation, Akishima, Tokyo, Japan.
- Rigaku/MSC (2004). *CrystalStructure*. Version 3.60. Rigaku/MSC, The Woodlands, Texas, USA.
- Sheldrick, G. M. (1997). *SHELXS97*. University of Göttingen, Germany.
- Yanagisawa, H., Ishihara, S., Ando, A., Kanazaki, T., Miyamoto, S., Koike, H., Iijima, Y., Oizumi, K., Matsushita, Y. & Hata, T. (1987). *J. Med. Chem.* **30**, 1984–1991.